Systematic review of cost‐of‐illness studies in hand eczema

Politiek, Klaziena; Oosterhaven, Jart A F; Vermeulen, Karin M.; Schuttelaar, Marie L A

doi:10.1111/cod.12590

Cited by 58 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, 40% of our cases (55/139) were attributable to occupational or combined exposure (Table ), with hand soap being the most common cause (15/55, 27.3%), as previously reported in the study of the French REVIDAL‐GERDA network . The relationship between lesion severity and sick leave rates and economic impact was comparable to that in other reports …”

Section: Discussionsupporting

confidence: 89%

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

et al. 2019

View full text Add to dashboard Cite

Background Methylisothiazolinone (MI) is a preservative that is responsible for an epidemic of allergic contact dermatitis (ACD). Few studies have been published on the prognosis of patients with MI‐induced ACD. Objectives To evaluate relapses of MI‐induced ACD and difficulties in avoiding MI in patients who had received avoidance advice. Methods A retrospective study of patients with MI‐induced ACD diagnosed in two specialized dermato‐allergology units between 2010 and 2015 was performed. The median follow‐up was 3 years. Results Relapses were observed in 64% of 139 included patients, and were severe in 18%. Rinse‐off cosmetics were responsible for the largest proportion of relapses (27%). The median time to relapse was 5 months. Sixty‐nine per cent of relapses were on the hands, and 29% were on the face. Risk factors for relapsing were hand eczema and a personal history of atopy. The main difficulties encountered in the avoidance strategy were hidden sources of MI, the lack of labelling on industrial products, the complexity of cosmetic labelling, and remembering the name of the allergen. Conclusion MI‐induced ACD has a poor prognosis. Its high rate of relapse is mainly attributable to the difficulties of avoidance. Management needs to be improved. Specialized follow‐up in the year following diagnosis is essential to educate patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As compared with other more high-profile diseases, HE has until now occupied very little space in the public debate on health politics. 5,6 Since HE is often caused or aggravated by exposures in the workplace, the cost of sick leave, workers compensation and rehabilitation is huge. HE is defined as an eczema/dermatitis located on the hands and/or wrists.…”

Section: Introductionmentioning

confidence: 99%

Hand eczema: epidemiology, prognosis and prevention

Agner

Elsner

2019

Acad Dermatol Venereol

104

103

View full text Add to dashboard Cite

Hand eczema (HE) is a heterogeneous and often chronic disease located to the hands and wrist, and frequently associated with eczema on the feet. The aetiology is diverse, and the eczema may present with a variety of clinical symptoms. Acute and chronic stages appear; severity varies from mild to moderate and severe, and flares may be frequently recurrent or rare. The divergent aetiology and varied morphology of HE is sometimes tricky and may be challenging to the dermatologist. This review has focus on epidemiology, prognosis and prevention of HE, and intends to point towards some practical advice on how to diagnose, inform and guide HE patients.

show abstract

“…Despite treatment, up to 65% of patients are burdened with intermittent HE after 5 years (Veien et al, ), and 15% of patients were reportedly very satisfied with their treatment while 26% were somewhat or very dissatisfied (Dibenedetti, Baranowski, Zelt, Reynolds, & Sherrill, ). Additionally, the mean annual total cost per HE patient ranges from €1,712 to €9,792 ($1980–$11,327; Politiek, Oosterhaven, Vermeulen, & Schuttelaar, ). It is clear that safer and more effective therapeutics are needed for CHE.…”

Section: Introductionmentioning

confidence: 99%

Current and emerging therapies for hand eczema

Lee

Maarouf

Hendricks

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Although hand eczema (HE) and chronic hand eczema (CHE) are common conditions with significant disease burden, they traditionally have had limited treatment options beyond topical and short‐term systemic corticosteroids. We reviewed published and preliminary evidence on the current and emerging topical and systemic therapeutic agents for HE and CHE. The etiologies of various HE subtypes are discussed, and remaining knowledge and practice gaps are highlighted to encourage further investigations. A comprehensive search of http://clinicaltrials.gov and PubMed was completed for clinical trials that utilized known and emerging treatment options for HE and CHE. Several agents that target IL‐4 and IL‐13 signaling, keratinocyte proliferation, inflammatory cytokine production, bacterial protein synthesis, and inflammatory mediator (TNF‐α, JAK1, JAK2, and JAK3) proliferation are shown to be involved in the pathogenesis of CHE. Systemic agents include dupilumab, alitretinoin, acitretin, cyclosporine, azathioprine, and probiotics. Topical agents include delgocitinib, retapamulin, halometasone/triclosan, calcipotriol/betamethasone, tacrolimus, and pimecrolimus. These modalities have demonstrated varying degrees of clinical efficacy, evaluated by subjective assessments and scoring indexes. Targeted therapies are emerging for HE, but options are still limited, partially due to our narrow understanding of this heterogeneous condition. Additional and targeted therapeutic options are needed to match the rising prevalence and burden of HE. Keypoints Hand eczema (HE) is a heterogenous dermatosis with limited therapeutic options due to a lack of international guidelines regarding classification of HE subtypes and treatment. This review discusses current and emerging topical and systemic agents and their efficacies in the treatment of different types of hand eczema.

show abstract

Systematic review of cost‐of‐illness studies in hand eczema

Cited by 58 publications

References 24 publications

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

Hand eczema: epidemiology, prognosis and prevention

Current and emerging therapies for hand eczema

Contact Info

Product

Resources

About